Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Tissue_Regenix_Wound_Care
|
| gptkbp:awards |
Best Innovation Award 2018
|
| gptkbp:CEO |
Antony_Odell
|
| gptkbp:clinicalTrials |
cardiovascular devices
cartilage repair orthopedic implants wound healing products soft tissue repair bone repair various regenerative therapies |
| gptkbp:collaborations |
various academic institutions
|
| gptkbp:communityEngagement |
educational programs
healthcare_initiatives |
| gptkbp:financialPerformance |
publicly traded
revenue growth profitability goals |
| gptkbp:focus |
regenerative medicine
|
| gptkbp:founded |
2006
|
| gptkbp:futurePlans |
increase market share
enhance research capabilities expand product line |
| gptkbp:headquarters |
gptkb:York,_England
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tissue Regenix Group
|
| gptkbp:investmentFocus |
£10 million funding round 2020
|
| gptkbp:market |
gptkb:Asia
gptkb:USA Europe orthopedics wound care cardiovascular |
| gptkbp:partnerships |
gptkb:University_of_Manchester
gptkb:NHS gptkb:NHS_Blood_and_Transplant |
| gptkbp:patentCitation |
multiple patents in regenerative medicine
|
| gptkbp:products |
dCELL_technology
|
| gptkbp:regulatoryCompliance |
CE_Mark_for_products
FDA_clearance_for_products |
| gptkbp:researchFocus |
biomaterials
tissue engineering cellular therapies |
| gptkbp:researchInterest |
gptkb:University_of_Leeds
|
| gptkbp:subsidiary |
Tissue_Regenix_Orthopedics
Tissue_Regenix_Wound_Care |
| gptkbp:sustainabilityInitiatives |
ethical sourcing
recycling programs environmental responsibility |
| gptkbp:technology |
tissue regeneration
decellularization |
| gptkbp:tradedOn |
gptkb:London_Stock_Exchange
|
| gptkbp:website |
www.tissueregenix.com
|